Minimal clinically important difference (MCID) can be defined as the smallest change or difference in an outcome measure that is perceived as beneficial and would lead to a change in the patient’s medical management. The aim of the current expert consensus report is to provide a “state-of-the-art” review of the currently available literature evidence about MCID for end-points to monitor asthma control, in order to facilitate optimal disease management and identify unmet needs in the field to guide future research. A series of MCID cut-offs are currently available in literature and validated among populations of asthmatic patients, with most of the evidence focusing on outcomes as patient reported outcomes, lung function and exercise tolerance. On the contrary, only scant and partial data are available for inflammatory biomarkers. These clearly represent the most interesting target for future development in diagnosis and clinical management of asthma, particularly in view of the several biologic drugs in the pipeline, for which regulatory agencies will soon require personalised proof of efficacy and treatment response predictors.

Bonini M., Di Paolo M., Bagnasco D., Baiardini I., Braido F., Caminati M., et al. (2020). Minimal clinically important difference for asthma endpoints: An expert consensus report [10.1183/16000617.0137-2019].

Minimal clinically important difference for asthma endpoints: An expert consensus report

Scichilone N.;
2020

Abstract

Minimal clinically important difference (MCID) can be defined as the smallest change or difference in an outcome measure that is perceived as beneficial and would lead to a change in the patient’s medical management. The aim of the current expert consensus report is to provide a “state-of-the-art” review of the currently available literature evidence about MCID for end-points to monitor asthma control, in order to facilitate optimal disease management and identify unmet needs in the field to guide future research. A series of MCID cut-offs are currently available in literature and validated among populations of asthmatic patients, with most of the evidence focusing on outcomes as patient reported outcomes, lung function and exercise tolerance. On the contrary, only scant and partial data are available for inflammatory biomarkers. These clearly represent the most interesting target for future development in diagnosis and clinical management of asthma, particularly in view of the several biologic drugs in the pipeline, for which regulatory agencies will soon require personalised proof of efficacy and treatment response predictors.
Settore MED/10 - Malattie Dell'Apparato Respiratorio
Bonini M., Di Paolo M., Bagnasco D., Baiardini I., Braido F., Caminati M., et al. (2020). Minimal clinically important difference for asthma endpoints: An expert consensus report [10.1183/16000617.0137-2019].
File in questo prodotto:
File Dimensione Formato  
Bonini_ERR_20.full.pdf

accesso aperto

Descrizione: articolo principale
Tipologia: Versione Editoriale
Dimensione 468 kB
Formato Adobe PDF
468 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10447/492751
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 30
  • ???jsp.display-item.citation.isi??? 27
social impact